pat-1251
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2016 (NCT02852551)
Timeline
Indications
Mechanism of action
- Lysyl oxidase homolog 2INHIBITOR
LOXL2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- pat-1251
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04054245 | Phase 2 | Jul 24, 2019 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT02852551 | Phase 1 | Jul 1, 2016 | PharmAkea, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2019 |
| PharmAkea, Inc. | For profit | 1 | 1 | 1 | 2016 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2019 |
3 organizations
Page 1 / 1